<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047189</url>
  </required_header>
  <id_info>
    <org_study_id>00007137</org_study_id>
    <nct_id>NCT01047189</nct_id>
  </id_info>
  <brief_title>Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris</brief_title>
  <official_title>Adherence to ZIANA (Clindamycin Phosphate 1.2% With Tretinoin 0.025%)Gel Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicis Pharmaceutical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the effectiveness of two different types
      of topical acne medication.  This study will help to determine if one combined medication
      results in better acne improvement than two separate medications for acne.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Measured Adherence to ZIANA Gel or Generic Topical Clindamycin 1% Gel Each Morning Plus Generic Topical Tretinoin 0.025% Cream Each Evening in Subjects With Mild to Moderate Acne</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of prescribed doses taken as measured by a Medication Event Monitoring System (MEMS) cap</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change (Dynamic Assessment) From Baseline to Week 12 (or End of Treatment) in Total Acne Lesion Count</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Generic clindamycin 1% gel plus tretinoin 0.025% cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clindamycin phosphate 1.2% and tretinoin 0.025%</intervention_name>
    <description>applied once daily for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ziana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clindamycin 1% gel</intervention_name>
    <description>Topical clindamycin applied each morning for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tretinoin 0.025% cream</intervention_name>
    <description>Tretinoin 0.025% cream each evening for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or Females 12 years of age or older with a diagnosis of mild to moderate acne
             vulgaris.

          -  Subjects must sign written informed consent and agree to come for all study visits.

        Exclusion Criteria:

          -  Use of experimental drugs within 1 month prior to initiation of study therapy.

          -  Pregnant and nursing females will not be allowed in the study, and females of
             childbearing potential will have a pregnancy test at baseline.  Females of
             childbearing potential must agree to use approved birth control methods for the
             duration of the study.

          -  Use of systemic retinoids within 2 months of enrollment, use of any topical
             retinoids, systemic antibiotics, nicotinamide, systemic steroids or any other
             medication that may confound the results of the study within 1 month prior to start
             of the study

          -  Use of any other topical medications for acne, including cosmetics containing
             retinol, within 2 weeks prior to study entry.

          -  Any skin condition or disease that may require concurrent therapy or may confound the
             evaluation;

          -  History of hypersensitivity to any of the formulation components;

          -  Facial skin cancer or facial actinic keratosis;

          -  Use of any photosensitizing agents.

          -  Use of isotretinoin within the last 6 months.

          -  Chemical peels, microdermabrasion or laser resurfacing within 3 months of study
             entry.

          -  Crohns disease, ulcerative colitis, or have developed colitis with past antibiotic
             use.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven R Feldman, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences, Dermatology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 9, 2011</lastchanged_date>
  <firstreceived_date>January 11, 2010</firstreceived_date>
  <firstreceived_results_date>July 1, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest University</investigator_affiliation>
    <investigator_full_name>Steven R. Feldman</investigator_full_name>
    <investigator_title>Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Mild to moderate acne vulgaris</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
